|
|
|
| The Expression of Serum Nesfatin-1 and Omentin-1 in Patients with Polycystic Ovary Syndrome and Their Relationship with Insulin Resistance |
| WEI Xinyi, et al |
| School of Medicine, Wuhan University of Science and Technology, Hubei Wuhan 430065, China |
|
|
|
|
Abstract Objective: To investigate the expression of serum Nesfatin-1 and Omentin-1 in patients with polycystic ovary syndrome (PCOS) and their relationship with insulin resistance (IR). Methods: From January 2023 to June 2024, 93 PCOS patients who received treatment in our hospital were included as the study group. According to the steady-state model of insulin resistance index (HOMA-IR), they were separated into a combined IR group of 42 cases and a non IR group of 51 cases. 58 healthy individuals who underwent physical examinations were included as the control group, and general data were collected. Fully automatic biochemical analyzer was applied to analyze serum biochemical indicators. ELISA method was applied to detect serum Nesfatin-1 and Omentin-1. Pearson correlation was applied to analyze the serum levels of Nesfatin-1 and Omentin-1 in the study group, and their correlation with IR related indicators. Logistic regression was applied to analyze the influencing factors of insulin resistance in PCOS patients. ROC curve was applied to analyze the diagnostic value of serum fasting insulin (FINS), Nesfatin-1, and Omentin-1 levels for insulin resistance in PCOS patients. Results: Compared to the control group, the research group exhibited significantly higher BMI (27.55±2.46 VS 23.28±2.07), waist-to-hip ratio (0.86±0.13 VS 0.78±0.11), FBG (4.79±1.23 VS 3.64±0.72), FINS (13.49±2.56 VS 9.62±2.05), HOMA-IR (2.93±0.74 VS 1.56±0.31), TC (4.36±0.93 VS 3.95±0.85), TG (2.26±0.55 VS 1.46±0.26), and LDL-C (2.95±0.45 VS 2.48±0.39). Meanwhile, the expression levels of HDL-C (1.14±0.25 VS 1.28±0.29), Nesfatin-1 (18.27±4.39 VS 29.83±6.88), and Omentin-1 (64.59±8.39 VS 82.16±14.88) were notably lower in the research group than in the control group (t=2.722~13.373, P<0.05). The BMI (26.23±2.04 VS 28.64±2.37), waist-to-hip ratio (0.82±0.09 VS 0.89±0.11), FBG (3.88±0.86 VS 5.54±1.14), FINS (11.76±1.55 VS 14.91±2.24), HOMA-IR (2.03±0.64 VS 3.67±0.92), TC (4.15±0.69 VS 4.53±0.77), TG (2.06±0.38 VS 2.42±0.50), and LDL-C (2.83±0.31 VS 3.05±0.37) in the non-IR group were significantly lower than those in the combined IR group. Meanwhile, HDL-C (1.27±0.22 VS 1.03±0.18), Nesfatin-1 (20.65±3.16 VS 16.31±2.87), and Omentin-1 (71.94±7.72 VS 58.54±6.97) were significantly higher in the non-IR group than in the combined IR group (t=2.481~9.765, P<0.05). Pearson analysis revealed that serum levels of Nesfatin-1 and Omentin-1 were negatively correlated with BMI, waist-to-hip ratio, FBG, FINS, TG, and LDL-C (r=-0.429, -0.495, -0.447, -0.378, -0.439, P<0.05) (r=-0.408, -0.508, -0.435, -0.632, -0.412, -0.419, P<0.05), positively correlated with HDL-C (r=0.445, P<0.05) (r=0.429, P<0.05), and positively correlated between Nesfatin-1 and Omentin-1 levels (r=0.485, P<0.05). Logistic analysis indicated that FINS [OR/95% CI=2.631 (1.051~6.584)], Nesfatin-1 [OR/95% CI=0.589 (0.430~0.808)], and Omentin-1 [OR/95% CI=0.697 (0.541~0.898)] were influencing factors of insulin resistance (IR) in patients with polycystic ovary syndrome (PCOS)(P<0.05). ROC analysis showed that the AUC of FINS, Nesfatin-1, and Omentin-1 levels for diagnosing IR in PCOS patients was 0.866, 0.871, and 0.869, respectively. The AUC of the combined diagnosis of the three was 0.953, which was obviously higher than that of the individual diagnosis (Z triple combination - FINS=2.069, P=0.039; Z triple combination - Nesfatin-1=2.037, P=0.042; Z triple combination - Omentin-1=1.998, P=0.046). Conclusion: Patients with Polycystic Ovary Syndrome (PCOS) exhibit downregulation of Nesfatin-1 and Omentin-1 levels, and their changes are closely correlated with insulin resistance (IR). The combined detection of these two factors and fasting insulin (FINS) levels holds high diagnostic value for PCOS combined with IR.
|
|
|
|
|
|
[1] Demirc Altekin M,Caniklioglu A,Eris Yalcin S,et al.DLK1 and Nesfatin-1 levels and the relationship with metabolic parameters in polycystic ovary syndrome:prospective,controlled study[J].Turk Obstet Gynecol,2021,18(2):124-130. [2] Dong XC,Liu C,Zhuo GC,et al.Potential roles of mtDNA mutations in PCOS-IR:a review[J].Diabetes Metab Syndr Obes,2023,16(1):139-149. [3] Huang K,Liang Y,Ma Y,et al.The variation and correlation of serum adiponectin,nesfatin-1,IL-6,and TNF-α levels in prediabetes[J].Front Endocrinol (Lausanne),2022,13(1):774272. [4] Eimal Latif AH,Anwar S,Gautha,KS,et al.Association of plasma omentin-1 levels with diabetes and its complications[J].Cureus,2021,13(9):18203-18206. [5] Teede H J,Tay C T,Laven J J E,et al.Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J].Clin Endocrinol Metab,2023,108(10):2447-2469. [6] Chen W,Pang Y.Metabolic syndrome and PCOS:pathogenesis and the role of metabolites[J].Metabolites,2021,11(12):869-886. [7] Armanini D,Boscaro M,Bordin L,et al.Controversies in the pathogenesis,diagnosis and treatment of PCOS:focus on insulin resistance,inflammation,and hyperandrogenism[J].Int Mol Sci,2022,23(8):4110-4121. [8] Hamed EA,Sayyed HG,Abbas AM,et al.Nesfatin-1,dopamine,and NADPH levels in infertile women with polycystic ovary syndrome:is there a relationship between their levels and metabolic and hormonal variables[J].Reprod Infertil,2022,23(3):160-168. [9] Sabzevari F,Mogharnasi M,Golestani F.Effect of 6 weeks Pilates training along with dill supplementation on serum concentrations of nesfatin-1,lipocalin-2,and insulin resistance in females with overweight and obesity:a randomized controlled trial[J].Res Med Sci,2022,27(1):59-66. [10] Dooxa Nongrum A,Geue SR,K J N,et al.Analysing adipokine Omentin-1 in periodontal disease and type-2 diabetes mellitus:an interventional comparative study[J].Oral Biol Craniofac Res,2022,12(2):273-278. [11] Anthasri A,Ananthanarayanan PH,Veena P.A study on omentin-1 and prostate specific antigen in women on treatment for polycystic ovary syndrome[J].Indian Clin Biochem,2019,34(1):108-114. [12] 赵传志,陈凤玲.德谷胰岛素联合GLP-1 RAs对2型糖尿病患者Omentin-1、VaspinRBP4水平的影响[J].河北医药,2022,44(5):704-707. [13] 王玉红,张忠强,卢静,等.多囊卵巢综合征患者血清Omentin、CTRP9、Vaspin表达水平及临床意义[J].生殖医学杂志,2022,31(10):1410-1414. |
|
|
|